medullary breast cancer triple-negative

Release time ：Dec-23,2024

Medullary triple-negative breast cancer is a distinct subtype of breast cancer defined by the absence of estrogen receptors, progesterone receptors, and human epidermal growth factor receptor 2 (HER2) in the tumor cells. This subtype is typically unresponsive to hormonal therapies and HER2-targeted treatments, leaving limited treatment options.

For patients with medullary triple-negative breast cancer, treatment can be more challenging due to the lack of these three receptors, rendering conventional endocrine and HER2-targeted therapies ineffective. The primary therapeutic strategies are therefore surgery, radiotherapy, and chemotherapy. Surgical options include breast-conserving surgery or mastectomy, with the decision on lymph node dissection being made based on individual circumstances. Radiotherapy is generally administered postoperatively to minimize the risk of local recurrence. Chemotherapy, which involves the use of drugs to eliminate cancer cells, may necessitate more aggressive regimens for triple-negative breast cancer.

It is advised that patients with medullary triple-negative breast cancer stay informed about the latest research developments and seek comprehensive treatment advice from a multidisciplinary team. Additionally, maintaining healthy lifestyle habits, such as a balanced diet, regular exercise, and refraining from smoking and excessive alcohol consumption, can enhance treatment outcomes and overall quality of life. Throughout the treatment journey, it is crucial to adhere to medical guidance, engage in regular check-ups and monitoring, and make timely adjustments to the treatment plan as needed.